HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Physician Group Support Boosts OTC Contraception Chances

This article was originally published in The Tan Sheet

Executive Summary

The American College of Obstetricians and Gynecologists and the American Academy of Pediatrics recommend OTC availability of hormonal contraception, but pharmaceutical industry Rx-to-OTC switch sponsors remain elusive.

You may also be interested in...



Judge Likely To Order Lower Age Restriction For Emergency Contraceptives

A federal judge seems inclined to order FDA to make emergency contraceptives available OTC to women younger than 17, but he did not say whether the use would be limited to Teva’s Plan B One-Step, or would include all nonprescription levonorgestrel products.

Birth Control Primed For Switch

A new paradigm for nonprescription approvals could eliminate the risk of self-selecting a birth control drug, with some contraindications might likely not apparent, by having pharmacists provide counseling and screening or having women use a self-assessment tool with a standard algorithm.

FDA Analysis Finds Plan B Safe For Children

FDA found only 13 reports of serious pediatric AERs following ingestion of original two-dose Plan B or one-dose Plan B One-Step. In a review released Jan. 27, Office of Surveillance and Epidemiology officials said the data do not causally link the majority of pediatric AERs definitively to the drug.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS124797

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel